Robert C Bast

List of Publications by Year
in descending order

500	54,610	1893	1461
papers	citations	102 h-index	220 g-index

521	521	521	52995
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
3	American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. Journal of Clinical Oncology, 2007, 25, 5287-5312.	1.6	1,998
4	A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer. New England Journal of Medicine, 1983, 309, 883-887.	27.0	1,950
5	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 582	9.1	1,430
6	Reactivity of a monoclonal antibody with human ovarian carcinoma.. Journal of Clinical Investigation, 1981, 68, 1331-1337.	8.2	1,405
7	ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer. Journal of Clinical Oncology, 2006, 24, 5313-5327.	1.6	1,353
8	The biology of ovarian cancer: new opportunities for translation. Nature Reviews Cancer, 2009, 9, 415-428.	28.4	1,172
9	Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews Cancer, 2011, 11, 719-725.	28.4	1,084
10	Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer. Cancer Research, 2004, 64, 5882-5890.	0.9	884
11	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nature Reviews Cancer, 2015, 15, 668-679.	28.4	839
12	2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*. Journal of Clinical Oncology, 2001, 19, 1865-1878.	1.6	770
13	Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Hematopoietic Reconstitution after High-Dose Chemotherapy and Autologous Bone Marrow Transplantation. New England Journal of Medicine, 1988, 318, 869-876.	27.0	757
14	Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 11960-11965.	7.1	715
15	A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecologic Oncology, 2009, 112, 40-46.	1.4	702
16	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2016, 34, 1134-1150.	1.6	683
17	The CA 125 tumour-associated antigen: a review of the literature. Human Reproduction, 1989, 4, 1-12.	0.9	675
18	The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecologic Oncology, 2008, 108, 402-408.	1.4	594

#	Article	IF	Citations
19	Regulation of tumour necrosis factor-Î± processing by a metalloproteinase inhibitor. Nature, 1994, 370, 558-561.	27.8	583
20	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers. Clinical Chemistry, 2008, 54, e11-e79.	3.2	539
21	High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.. Journal of Clinical Oncology, 1993, 11, 1132-1143.	1.6	491
22	Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.. Journal of Clinical Oncology, 1996, 14, 2843-2877.	1.6	486
23	New tumor markers: CA125 and beyond. International Journal of Gynecological Cancer, 2005, 15, 274-281.	2.5	424
24	Selection of Potential Markers for Epithelial Ovarian Cancer with Gene Expression Arrays and Recursive Descent Partition Analysis. Clinical Cancer Research, 2004, 10, 3291-3300.	7.0	399
25	High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.. Journal of Clinical Oncology, 1988, 6, 1368-1376.	1.6	375
26	The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. Journal of Clinical Investigation, 2008, 118, 3917-29.	8.2	370
27	Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer. Molecular Cancer Therapeutics, 2010, 9, 3186-3199.	4.1	343
28	Immunopathologic Characterization of a Monoclonal Antibody that Recognizes Common Surface Antigens of Human Ovarian Tumors of Serous, Endometrioid, and Clear Cell Types. American Journal of Clinical Pathology, 1983, 79, 98-104.	0.7	338
29	BCG and Cancer. New England Journal of Medicine, 1974, 290, 1413-1420.	27.0	334
30	Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecologic Oncology, 2005, 99, 267-277.	1.4	324
31	Elevated serum concentrations of CA-125 in patients with advanced endometriosis. Fertility and Sterility, 1986, 45, 630-634.	1.0	313
32	The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 16472-16477.	7.1	292
33	NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 214-219.	7.1	289
34	Patterns of Gene Expression in Different Histotypes of Epithelial Ovarian Cancer Correlate with Those in Normal Fallopian Tube, Endometrium, and Colon. Clinical Cancer Research, 2005, 11, 6116-6126.	7.0	283
35	Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2015, 33, 2695-2704.	1.6	279
36	Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer, 2012, 118, 2603-2614.	4.1	265

#	Article	IF	Citations
37	Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. American Journal of Obstetrics and Gynecology, 1984, 148, 1057-1058.	1.3	262
38	A Genetically Defined Model for Human Ovarian Cancer. Cancer Research, 2004, 64, 1655-1663.	0.9	259
39	Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens. Cancer Prevention Research, 2011, 4, 365-374.	1.5	256
40	Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. American Journal of Obstetrics and Gynecology, 1991, 164, 15-21.	1.3	254
41	Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Molecular Carcinogenesis, 2008, 47, 701-706.	2.7	249
42	Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy. Endocrinology, 2012, 153, 1593-1602.	2.8	248
43	Development of a Multimarker Assay for Early Detection of Ovarian Cancer. Journal of Clinical Oncology, 2010, 28, 2159-2166.	1.6	246
44	Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene, 1999, 18, 6635-6640.	5.9	242
45	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. Journal of Clinical Oncology, 2017, 35, 2838-2847.	1.6	241
46	Early Detection of Ovarian Cancer. Disease Markers, 2007, 23, 397-410.	1.3	223
47	Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. American Journal of Obstetrics and Gynecology, 2010, 203, 228.e1-228.e6.	1.3	219
48	Prospective Study Using the Risk of Ovarian Cancer Algorithm to Screen for Ovarian Cancer. Journal of Clinical Oncology, 2005, 23, 7919-7926.	1.6	218
49	Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer, 1995, 76, 2004-2010.	4.1	209
50	Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. American Journal of Obstetrics and Gynecology, 1991, 164, 669-674.	1.3	205
51	Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses. Discrimination of benign from malignant disease. American Journal of Obstetrics and Gynecology, 1988, 159, 341-346.	1.3	200
52	BCG and Cancer. New England Journal of Medicine, 1974, 290, 1458-1469.	27.0	197
53	Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers. International Journal of Gynecological Cancer, 2016, 26, 43-51.	2.5	195
54	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Updateâ€"Integration of Results From TAILORx. Journal of Clinical Oncology, 2019, 37, 1956-1964.	1.6	189

#	Article	IF	Citations
55	Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecologic Oncology, 2008, 110, 196-201.	1.4	184
56	Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. American Journal of Obstetrics and Gynecology, 1985, 151, 981-986.	1.3	178
57	Status of Tumor Markers in Ovarian Cancer Screening. Journal of Clinical Oncology, 2003, 21, 200s-205.	1.6	178
58	Cell Origins of High-Grade Serous Ovarian Cancer. Cancers, 2018, 10, 433.	3.7	176
59	AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: Advancing the Use of Biomarkers in Cancer Drug Development. Clinical Cancer Research, 2010, 16, 3299-3318.	7.0	175
60	Activated Src Protein Tyrosine Kinase Is Overexpressed in Late-Stage Human Ovarian Cancers. Gynecologic Oncology, 2003, 88, 73-79.	1.4	172
61	Mechanisms for Lysophosphatidic Acid-induced Cytokine Production in Ovarian Cancer Cells. Journal of Biological Chemistry, 2004, 279, 9653-9661.	3.4	172
62	Communication skills training in oncology. , 1999, 86, 887-897.		170
63	Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen. American Journal of Obstetrics and Gynecology, 1984, 149, 553-559.	1.3	161
64	High dose methotrexate with leucovorin rescue. American Journal of Medicine, 1980, 68, 370-376.	1.5	160
65	A Framework for Evaluating Biomarkers for Early Detection: Validation of Biomarker Panels for Ovarian Cancer. Cancer Prevention Research, 2011, 4, 375-383.	1.5	160
66	The p53 tumor suppressor gene frequently is altered in gynecologic cancers. American Journal of Obstetrics and Gynecology, 1994, 170, 246-252.	1.3	157
67	Preoperative Sensitivity and Specificity for Early-Stage Ovarian Cancer When Combining Cancer Antigen CA-125II, CA 15-3, CA 72-4, and Macrophage Colony-Stimulating Factor Using Mixtures of Multivariate Normal Distributions. Journal of Clinical Oncology, 2004, 22, 4059-4066.	1.6	156
68	Phase 1bâ€2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinumâ€resistant or platinumâ€refractory epithelial ovarian cancer. Cancer, 2011, 117, 1661-1669.	4.1	156
69	HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene, 2006, 25, 6986-6996.	5.9	154
70	Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer, 1994, 73, 2380-2385.	4.1	150
71	Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently downâ€regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer, 2008, 112, 1489-1502.	4.1	149
72	Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. Oncogene, 1997, 15, 2589-2596.	5.9	146

#	Article	IF	Citations
73	Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Human Pathology, 1996, 27, 1185-1191.	2.0	143
74	Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. Cancer Cell, 2016, 30, 273-289.	16.8	143
75	Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemicâ€‰therapy. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 15346-15351.	7.1	143
76	Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. Molecular Cell, 2016, 61, 520-534.	9.7	142
77	1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology.. Journal of Clinical Oncology, 1998, 16, 793-795.	1.6	141
78	Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel Chemotherapy. Clinical Cancer Research, 2005, 11, 2149-2155.	7.0	139
79	Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecologic Oncology, 2010, 117, 440-445.	1.4	133
80	The Role of Cyclin-dependent Kinase Inhibitor p27Kip1 in Anti-HER2 Antibody-induced G1 Cell Cycle Arrest and Tumor Growth Inhibition. Journal of Biological Chemistry, 2003, 278, 23441-23450.	3.4	132
81	HER2-targeting Antibodies Modulate the Cyclin-dependent Kinase Inhibitor p27Kip1 via Multiple Signaling Pathways. Cell Cycle, 2005, 4, 87-95.	2.6	131
82	The p53 tumor suppressor gene frequently is altered in gynecologic cancers. American Journal of Obstetrics and Gynecology, 1994, 170, 246-252.	1.3	130
83	Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Research, 2007, 9, R57.	5.0	130
84	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clinic Proceedings, 2015, 90, 996-1000.	3.0	128
85	SIK2 Is a Centrosome Kinase Required for Bipolar Mitotic Spindle Formation that Provides a Potential Target for Therapy in Ovarian Cancer. Cancer Cell, 2010, 18, 109-121.	16.8	126
86	CA 125 Serum Levels Correlated With Second-Look Operations Among Ovarian Cancer Patients. Obstetrics and Gynecology, 1986, 67, 685-689.	2.4	121
87	Linking genomic reorganization to tumor initiation via the giant cell cycle. Oncogenesis, 2016, 5, e281-e281.	4.9	121
88	Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines.. Journal of Clinical Investigation, 1989, 83, 921-926.	8.2	121
89	The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer, 2006, 107, 2730-2740.	4.1	119
90	High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial.. Journal of Clinical Oncology, 1986, 4, 646-654.	1.6	118

#	Article	IF	Citations
91	Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer, 2011, 117, 4424-4438.	4.1	118
92	Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. American Journal of Obstetrics and Gynecology, 2012, 206, 349.e1-349.e7.	1.3	117
93	A 2â€stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies earlyâ€stage incident cancers and demonstrates high positive predictive value. Cancer, 2013, 119, 3454-3461.	4.1	117
94	Potent and Selective Phosphopeptide Mimetic Prodrugs Targeted to the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 3. Journal of Medicinal Chemistry, 2011, 54, 3549-3563.	6.4	116
95	Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. American Journal of Obstetrics and Gynecology, 2012, 206, 351.e1-351.e8.	1.3	116
96	Use of CA-125 in Clinical Trial Evaluation of New Therapeutic Drugs for Ovarian Cancer. Clinical Cancer Research, 2004, 10, 3919-3926.	7.0	115
97	Early Detection of Ovarian Cancer: Promise and Reality. Cancer Treatment and Research, 2002, 107, 61-97.	0.5	115
98	Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. International Journal of Cancer, 1994, 56, 552-559.	5.1	114
99	Activating and Propagating Polyclonal Gamma Delta T Cells with Broad Specificity for Malignancies. Clinical Cancer Research, 2014, 20, 5708-5719.	7.0	114
100	The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. American Journal of Obstetrics and Gynecology, 1986, 155, 56-60.	1.3	110
101	Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. American Journal of Obstetrics and Gynecology, 1991, 164, 745-750.	1.3	110
102	An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. Gynecologic Oncology, 1988, 30, 7-14.	1.4	107
103	Stanniocalcin 1 and Ovarian Tumorigenesis. Journal of the National Cancer Institute, 2010, 102, 812-827.	6.3	107
104	p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry.. Journal of Histochemistry and Cytochemistry, 1992, 40, 1047-1051.	2.5	103
105	CRITICAL REVIEW OF PREVIOUSLY REPORTED ANIMAL STUDIES OF TUMOR IMMUNOTHERAPY WITH NON-SPECIFIC IMMUNOSTIMULANTS. Annals of the New York Academy of Sciences, 1976, 277, 60-93.	3.8	102
106	The role of biomarkers in the management of epithelial ovarian cancer. Expert Review of Molecular Diagnostics, 2017, 17, 577-591.	3.1	102
107	Early Detection of Ovarian Cancer. Hematology/Oncology Clinics of North America, 2018, 32, 903-914.	2.2	102
108	Inhibition of Breast and Ovarian Tumor Growth through Multiple Signaling Pathways by Using Retrovirus-mediated Small Interfering RNA against Her-2/neu Gene Expression. Journal of Biological Chemistry, 2004, 279, 4339-4345.	3.4	101

#	Article	IF	Citations
109	ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene, 2003, 22, 2897-2909.	5.9	100
110	Regulation of growth of normal ovarian epithelial cells andovarian cancer cell lines by transforming growth factor-ÃŸ. American Journal of Obstetrics and Gynecology, 1992, 166, 676-684.	1.3	99
111	A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1. Human Molecular Genetics, 1994, 3, 589-594.	2.9	98
112	Regulation of Invasion of Epithelial Ovarian Cancer by Transforming Growth Factor-Î². Gynecologic Oncology, 2001, 80, 245-253.	1.4	97
113	Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-Î±. American Journal of Obstetrics and Gynecology, 1992, 166, 997-1007.	1.3	96
114	Combinations of Multiple Serum Markers Are Superior to Individual Assays for Discriminating Malignant from Benign Pelvic Masses. Gynecologic Oncology, 1995, 59, 111-116.	1.4	96
115	Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecologic Oncology, 2007, 107, 526-531.	1.4	96
116	OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma. Cancer, 2001, 92, 2837-2844.	4.1	94
117	Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecologic Oncology, 2010, 116, 240-245.	1.4	92
118	Prevention and Early Detection of Ovarian Cancer: Mission Impossible?. Recent Results in Cancer Research, 2007, 174, 91-100.	1.8	92
119	Prospective evaluation of serum CA 125 levels in a normal population, phase I: The specificities of single and serial determinations in testing for ovarian cancer. Gynecologic Oncology, 1990, 36, 299-305.	1.4	90
120	CA 125 in Ovarian Cancer: Advances and Controversy. Clinical Chemistry, 1998, 44, 1379-1380.	3.2	90
121	Clinically Relevant microRNAs in Ovarian Cancer. Molecular Cancer Research, 2015, 13, 393-401.	3.4	90
122	Somatic activation of rasK gene in a human ovarian carcinoma. Science, 1984, 223, 698-701.	12.6	89
123	Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer, 1995, 76, 2092-2096.	4.1	88
124	Transcriptional regulation of core autophagy and lysosomal genes by the androgen receptor promotes prostate cancer progression. Autophagy, 2017, 13, 506-521.	9.1	88
125	Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma. Gynecologic Oncology, 1985, 22, 115-120.	1.4	87
126	The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade. Cancer Microenvironment, 2010, 3, 137-147.	3.1	85

#	Article	IF	Citations
127	Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1Î±/cyclin D1 pathway. Oncogene, 2016, 35, 2506-2517.	5.9	85
128	4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial.. Journal of Clinical Oncology, 1991, 9, 85-93.	1.6	83
129	Characterization of Gelatinases Linked to Extracellular Matrix Invasion in Ovarian Adenocarcinoma: Purification of Matrix Metalloproteinase 2. Gynecologic Oncology, 1996, 62, 89-99.	1.4	82
130	Lysophosphatidic Acid Is a Major Regulator of Growth-Regulated Oncogene Î± in Ovarian Cancer. Cancer Research, 2006, 66, 2740-2748.	0.9	82
131	Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms. International Journal of Cancer, 1983, 32, 547-554.	5.1	81
132	Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas. American Journal of Obstetrics and Gynecology, 1994, 170, 1177-1183.	1.3	81
133	Epidermal growth factor receptor expression in normal and malignant endometrium. American Journal of Obstetrics and Gynecology, 1989, 161, 1247-1252.	1.3	80
134	The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways. Oncogene, 2012, 31, 68-79.	5.9	80
135	Serum levels of HER-2neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. Cancer, 1993, 71, 3942-3946.	4.1	78
136	Dasatinib induces autophagic cell death in human ovarian cancer. Cancer, 2010, 116, 4980-4990.	4.1	77
137	Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer, 2012, 118, 91-100.	4.1	77
138	Overexpression of MEKK3 Confers Resistance to Apoptosis through Activation of NFÎºB. Journal of Biological Chemistry, 2004, 279, 7576-7583.	3.4	75
139	Epigenetic Regulation of ARHI in Breast and Ovarian Cancer Cells. Annals of the New York Academy of Sciences, 2003, 983, 268-277.	3.8	74
140	Early detection of ovarian cancer. Biomarkers in Medicine, 2008, 2, 291-303.	1.4	74
141	Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecologic Oncology, 2012, 126, 47-53.	1.4	74
142	Overexpression of p53 Is Not a Feature of Benign and Early-Stage Borderline Epithelial Ovarian Tumors. Gynecologic Oncology, 1994, 52, 232-236.	1.4	73
143	Translational Crossroads for Biomarkers. Clinical Cancer Research, 2005, 11, 6103-6108.	7.0	73
144	Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecologic Oncology, 2011, 122, 548-553.	1.4	73

#	Article	IF	Citations
145	Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. American Journal of Obstetrics and Gynecology, 1991, 165, 1356-1362.	1.3	72
146	Cell growth regulation in epithelial ovarian cancer. Cancer, 1993, 71, 1597-1601.	4.1	72
147	Src family kinases and paclitaxel sensitivity. Cancer Biology and Therapy, 2011, 12, 260-269.	3.4	72
148	Autologous bone marrow transplantation for acute lymphoblastic leukemia.. Journal of Clinical Oncology, 1989, 7, 1594-1601.	1.6	71
149	Combination of Multiple Serum Markers Using an Artificial Neural Network to Improve Specificity in Discriminating Malignant from Benign Pelvic Masses. Gynecologic Oncology, 1999, 73, 56-61.	1.4	71
150	Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Research, 2003, 63, 4174-80.	0.9	71
151	Expression of p16 induces transcriptional downregulation of the RB gene. Oncogene, 1998, 16, 1-8.	5.9	70
152	Lysophosphatidylcholine Stimulates Activator Protein 1 and the c-Jun N-terminal Kinase Activity. Journal of Biological Chemistry, 1997, 272, 13683-13689.	3.4	69
153	Acquired cellular immunity: Extracellular killing of Listeria monocytogenes by a product of immunologically activated macrophages. Cellular Immunology, 1974, 10, 248-259.	3.0	67
154	Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecologic Oncology, 2003, 90, 44-50.	1.4	67
155	ARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXo3a-mediated induction of Rab7. Cell Death and Differentiation, 2014, 21, 1275-1289.	11.2	67
156	Contrasting effects of cyclophosphamide and prednisolone on the phenotype of human peripheral blood leukocytes. Clinical Immunology and Immunopathology, 1983, 28, 101-114.	2.0	65
157	Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites. Cancer, 1994, 74, 93-99.	4.1	65
158	Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecologic Oncology, 2007, 106, 490-497.	1.4	65
159	Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel. BMC Cancer, 2011, 11, 22.	2.6	65
160	Expression and amplification of the HER-2/ neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines. American Journal of Obstetrics and Gynecology, 1991, 165, 640-646.	1.3	64
161	Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation. Human Molecular Genetics, 2003, 12, 1791-1800.	2.9	64
162	Constitutive Production of Macrophage Colony-Stimulating Factor and Interleukin-6 by Human Ovarian Surface Epithelial Cells. Experimental Cell Research, 1993, 207, 332-339.	2.6	63

#	Article	IF	Citations
163	Future for Ovarian Cancer Screening: Novel Markers From Emerging Technologies of Transcriptional Profiling and Proteomics. Journal of the National Cancer Institute, 2001, 93, 1437-1439.	6.3	63
164	Differential Diagnosis of a Pelvic Mass. International Journal of Gynecological Cancer, 2012, 22, S5-S8.	2.5	63
165	Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. Carcinogenesis, 2007, 28, 174-182.	2.8	62
166	DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells. Autophagy, 2014, 10, 1071-1092.	9.1	62
167	Genes Affecting the Cell Cycle, Growth, Maintenance, and Drug Sensitivity Are Preferentially Regulated by Anti-HER2 Antibody through Phosphatidylinositol 3-Kinase-AKT Signaling. Journal of Biological Chemistry, 2005, 280, 2092-2104.	3.4	60
168	Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway. Cancer Research, 2002, 62, 7264-72.	0.9	60
169	Determination of Proliferation Index with MIB-1 in Advanced Ovarian Cancer Using Quantitative Image Analysis. American Journal of Clinical Pathology, 1994, 101, 192-197.	0.7	59
170	Expression of the Tumor Suppressor Gene ARHI in Epithelial Ovarian Cancer Is Associated with Increased Expression of p21WAF1/CIP1 and Prolonged Progression-Free Survival. Clinical Cancer Research, 2004, 10, 6559-6566.	7.0	59
171	Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle, 2008, 7, 3747-3758.	2.6	59
172	Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer. PLoS ONE, 2012, 7, e41170.	2.5	59
173	Lysophosphatidic acid prevents apoptosis in fibroblasts via Gi-protein-mediated activation of mitogen-activated protein kinase. Biochemical Journal, 2000, 352, 135.	3.7	58
174	Biomarkers, Surrogate End Points, and the Acceleration of Drug Development for Cancer Prevention and Treatment. Clinical Cancer Research, 2004, 10, 3881-3884.	7.0	58
175	Biochemistry and Biology of ARHI (DIRAS3), an Imprinted Tumor Suppressor Gene Whose Expression Is Lost in Ovarian and Breast Cancers. Methods in Enzymology, 2006, 407, 455-468.	1.0	58
176	Growth regulation and transformation of ovarian epithelium. Cancer, 1993, 71, 545-551.	4.1	58
177	Personalizing Therapy for Ovarian Cancer: BRCAness and Beyond. Journal of Clinical Oncology, 2010, 28, 3545-3548.	1.6	58
178	Phase I Study of Stealth Liposomal Doxorubicin in Combination With Gemcitabine in the Treatment of Patients With Metastatic Breast Cancer. Journal of Clinical Oncology, 2001, 19, 1716-1722.	1.6	57
179	CA 125 and the detection of recurrent ovarian cancer. Cancer, 2010, 116, 2850-2853.	4.1	57
180	Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias. American Journal of Obstetrics and Gynecology, 1993, 169, 690-694.	1.3	56

#	Article	IF	Citations
181	Low-grade serous carcinoma: New concepts and emerging therapies. Gynecologic Oncology, 2013, 130, 660-666.	1.4	56
182	Novel Approaches to Ovarian Cancer Screening. Current Oncology Reports, 2019, 21, 75.	4.0	56
183	The duke afm program intensive induction chemotherapy for metastatic breast cancer. Cancer, 1990, 66, 431-436.	4.1	55
184	Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. Oncogene, 2003, 22, 484-497.	5.9	55
185	Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers. BMC Cancer, 2010, 10, 378.	2.6	55
186	Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma. Epigenetics, 2013, 8, 1330-1346.	2.7	55
187	A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel. Clinical Cancer Research, 2017, 23, 1945-1954.	7.0	54
188	Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagyâ€mediated drug resistance in ovarian cancer cells, xenografts, and patientâ€derived xenograft models. Cancer, 2020, 126, 894-907.	4.1	54
189	Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer. Clinical Cancer Research, 2005, 11, 632-7.	7.0	54
190	Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbb-2 (her-2/neu) gene product p185. International Journal of Cancer, 1993, 53, 401-408.	5.1	53
191	Biomarkers and Strategies for Early Detection of Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2504-2512.	2.5	53
192	Adenovirus-Mediated p53 Growth Inhibition of Ovarian Cancer Cells Is Independent of Endogenous p53 Status. Gynecologic Oncology, 1999, 75, 261-266.	1.4	52
193	Transcriptional and Posttranscriptional Down-Regulation of the Imprinted Tumor Suppressor Gene ARHI (DRAS3) in Ovarian Cancer. Clinical Cancer Research, 2006, 12, 2404-2413.	7.0	52
194	High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. Gynecologic Oncology, 1990, 38, 386-391.	1.4	51
195	MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse. Differentiation, 2008, 76, 1081-1092.	1.9	51
196	Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC Cancer, 2012, 12, 243.	2.6	51
197	A Multiplexable, Microfluidic Platform for the Rapid Quantitation of a Biomarker Panel for Early Ovarian Cancer Detection at the Point-of-Care. Cancer Prevention Research, 2015, 8, 37-48.	1.5	51
198	Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. Clinical Cancer Research, 2003, 9, 3660-6.	7.0	51

#	Article	IF	Citations
199	ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts. Cell Death and Disease, 2015, 6, e1836-e1836.	6.3	50
200	Aryl hydrocarbon (benzo(a)pyrene) hydroxylase in human peripheral blood monocytes. Nature, 1974, 250, 664-665.	27.8	49
201	The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. American Journal of Obstetrics and Gynecology, 1990, 163, 1164-1167.	1.3	49
202	ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers. , 2000, 86, 690-694.		49
203	Progress in the Management of Gynecologic Cancer: Consensus Summary Statement. Journal of Clinical Oncology, 2003, 21, 129s-132.	1.6	49
204	More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis. Gynecologic Oncology, 2011, 121, 429-430.	1.4	49
205	Modulating Microtubule Stability Enhances the Cytotoxic Response of Cancer Cells to Paclitaxel. Cancer Research, 2011, 71, 5806-5817.	0.9	49
206	Co-expression of human cancer-associated epitopes on mucin molecules. International Journal of Cancer, 1987, 39, 68-72.	5.1	48
207	Individualized Care for Patients with Cancer â€" A Work in Progress. New England Journal of Medicine, 2004, 351, 2865-2867.	27.0	48
208	Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma. American Journal of Obstetrics and Gynecology, 1990, 163, 1204-1209.	1.3	47
209	Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support. Breast Cancer Research and Treatment, 1996, 41, 1-13.	2.5	47
210	Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer. Clinical Cancer Research, 2017, 23, 5912-5922.	7.0	47
211	Downregulation of TRIM27 expression inhibits the proliferation of ovarian cancer cells in vitro and in vivo. Laboratory Investigation, 2016, 96, 37-48.	3.7	46
212	Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma.. Journal of Clinical Oncology, 1985, 3, 1355-1363.	1.6	45
213	The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas. Oncology, 2013, 27, 548-56.	0.5	45
214	Fluorescence spectroscopy for in vivo characterization of ovarian tissue. Lasers in Surgery and Medicine, 2001, 29, 128-135.	2.1	44
215	Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nature Communications, 2018, 9, 476.	12.8	44
216	DIRAS3 (ARHI) Blocks RAS/MAPK Signaling by Binding Directly to RAS and Disrupting RAS Clusters. Cell Reports, 2019, 29, 3448-3459.e6.	6.4	44

#	Article	IF	Citations
217	Tumor necrosis factor-Î± and interferon-Î³ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFÎºB. Oncotarget, 2016, 7, 14871-14884.	1.8	44
218	Targeted therapy for epithelial ovarian cancer: Current status and future prospects. International Journal of Gynecological Cancer, 2003, 13, 701-734.	2.5	43
219	RAS-related GTPases DIRAS1 and DIRAS2 induce autophagic cancer cell death and are required for autophagy in murine ovarian cancer cells. Autophagy, 2018, 14, 637-653.	9.1	43
220	Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C Î± activity. Oncogene, 2001, 20, 8258-8269.	5.9	42
221	A Ras Homologue Member I Directly Inhibits Signal Transducers and Activators of Transcription 3 Translocation and Activity in Human Breast and Ovarian Cancer Cells. Cancer Research, 2005, 65, 6701-6710.	0.9	42
222	FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization. Cancer Research, 2011, 71, 6878-6887.	0.9	42
223	ALTERED IMMUNOLOGIC RECONSTITUTION AFTER STANDARD-DOSE CHEMOTHERAPY OR HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE MARROW SUPPORT. Transplantation, 1988, 46, 57-60.	1.0	41
224	Follicle-stimulating hormone inhibits apoptosis in ovarian cancer cells by regulating the OCT4 stem cell signaling pathway. International Journal of Oncology, 2013, 43, 1194-1204.	3.3	41
225	Ca 125 Assay Used in Conjunction with Ca 15â€“3 and Tag-72 Assays for Discrimination Between Malignant and Non-Malignant Diseases of the Ovary. Acta OncolÃ³gica, 1989, 28, 655-657.	1.8	40
226	Urinary levels of Bcl-2 are elevated in ovarian cancer patients. Gynecologic Oncology, 2009, 112, 60-67.	1.4	40
227	Paclitaxel inhibits ovarian tumor growth by inducing epithelial cancer cells to benign fibroblast-like cells. Cancer Letters, 2012, 326, 176-182.	7.2	40
228	Potentially inappropriate medication use in older patients with breast and colorectal cancer. Cancer, 2018, 124, 3000-3007.	4.1	40
229	Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvum. American Journal of Obstetrics and Gynecology, 1985, 152, 1003-1010.	1.3	39
230	Pathogenesis of Ovarian Cancers. Journal of the Society for Gynecologic Investigation, 1994, 1, 181-190.	1.7	39
231	Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Seminars in Oncology, 2003, 30, 93-104.	2.2	39
232	Combined use of biomarkers for detection of ovarian cancer in high-risk women. Tumor Biology, 2010, 31, 209-215.	1.8	39
233	Programmable Bio-Nano-Chip Systems for Serum CA125 Quantification: Toward Ovarian Cancer Diagnostics at the Point-of-Care. Cancer Prevention Research, 2012, 5, 706-716.	1.5	39
234	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer, 2019, 125, 1963-1972.	4.1	39

#	Article	IF	Citations
235	Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3. BJOG: an International Journal of Obstetrics and Gynaecology, 1993, 100, 1120-1124.	2.3	38
236	Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells. Molecular Cancer Therapeutics, 2007, 6, 2843-2857.	4.1	38
237	A Phase I Study of a Daily Ã—3 Schedule of Intravenous Vinorelbine for Refractory Epithelial Ovarian Cancer. Gynecologic Oncology, 1998, 70, 404-409.	1.4	37
238	Inhibition of growth-factor-induced phosphorylation and activation of protein kinase B/Akt by atypical protein kinase C in breast cancer cells. Biochemical Journal, 2000, 352, 475.	3.7	36
239	Genomic structure and promoter characterization of an imprinted tumor suppressor gene ARHI. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2001, 1519, 216-222.	2.4	36
240	Reflection on the Discovery of Carcinoembryonic Antigen, Prostate-Specific Antigen, and Cancer Antigens CA125 and CA19-9. Clinical Chemistry, 2013, 59, 22-31.	3.2	36
241	Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer. International Journal of Gynecological Cancer, 2016, 26, 1070-1077.	2.5	36
242	Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution. Nuclear Medicine and Biology, 1999, 26, 781-790.	0.6	35
243	Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1333-1340.	2.5	35
244	Pros and cons of gynecologic tumor markers. Cancer, 1987, 60, 1984-1992.	4.1	34
245	A novel hTERT promoterâ€“driven E1A therapeutic for ovarian cancer. Molecular Cancer Therapeutics, 2009, 8, 2375-2382.	4.1	34
246	Cyclin G1 regulates the outcome of taxane-induced mitotic checkpoint arrest. Oncogene, 2012, 31, 2450-2460.	5.9	34
247	Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies. EBioMedicine, 2016, 10, 137-149.	6.1	34
248	Weight Loss Upregulates the Small GTPase DIRAS3 in Human White Adipose Progenitor Cells, Which Negatively Regulates Adipogenesis and Activates Autophagy via Aktâ€“mTOR Inhibition. EBioMedicine, 2016, 6, 149-161.	6.1	34
249	CA125/MUC16 Is Dispensable for Mouse Development and Reproduction. PLoS ONE, 2009, 4, e4675.	2.5	34
250	Coevolution of neoplastic epithelial cells and multilineage stroma via polyploid giant cells during immortalization and transformation of mullerian epithelial cells. Genes and Cancer, 2016, 7, 60-72.	1.9	34
251	Detection of Breast Carcinoma Cells in Human Bone Marrow Using Fluorescence-Activated Cell Sorting and Conventional Cytology. American Journal of Clinical Pathology, 1990, 94, 8-13.	0.7	33
252	Regression of Established Tumors and Induction of Tumor Immunity by Intratumor Chemotherapy. Journal of the National Cancer Institute, 1976, 56, 829-832.	6.3	32

#	Article	IF	Citations
253	Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. American Journal of Obstetrics and Gynecology, 1994, 170, 1285-1296.	1.3	32
254	Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defined human ovarian cancer model. Oncogene, 2005, 24, 6174-6184.	5.9	32
255	Dissecting â€œPI3Knessâ€ The Complexity of Personalized Therapy for Ovarian Cancer. Cancer Discovery, 2012, 2, 16-18.	9.4	32
256	CA-125 Level as a Prognostic Indicator in Type I and Type II Epithelial Ovarian Cancer. International Journal of Gynecological Cancer, 2013, 23, 815-822.	2.5	32
257	A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis. Journal of Experimental Therapeutics and Oncology, 2012, 10, 155-62.	0.5	32
258	HETEROGENEITY OF THE CELLULAR IMMUNE RESPONSE. Journal of Experimental Medicine, 1971, 133, 202-215.	8.5	31
259	Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. American Journal of Obstetrics and Gynecology, 1994, 170, 1285-1296.	1.3	31
260	How Do You Distinguish a Malignant Pelvic Mass From a Benign Pelvic Mass? Imaging, Biomarkers, or None of the Above. Journal of Clinical Oncology, 2007, 25, 4159-4161.	1.6	31
261	FSH enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3. Endocrine-Related Cancer, 2013, 20, 415-429.	3.1	31
262	Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Clinical Cancer Research, 2018, 24, 5072-5084.	7.0	31
263	The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines. American Journal of Obstetrics and Gynecology, 1993, 168, 228-232.	1.3	30
264	Fluorescence spectroscopy as a biomarker in a cell culture and in a nonhuman primate model for ovarian cancer chemopreventive agents. Journal of Biomedical Optics, 2002, 7, 20.	2.6	30
265	IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming. Oncogenesis, 2021, 10, 65.	4.9	30
266	Synergistic Interaction between an Anti-p185HER-2 Pseudomonas Exotoxin Fusion Protein [scFv(FRP5)â€“ETA] and Ionizing Radiation for Inhibiting Growth of Ovarian Cancer Cells That Overexpress HER-2. Gynecologic Oncology, 2001, 80, 145-155.	1.4	29
267	Expression of BAG-1 and BcL-2 Proteins Before and After Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer. Cancer Investigation, 2004, 22, 248-256.	1.3	29
268	MEKK3 expression correlates with nuclear factor Î² B activity and with expression of antiapoptotic genes in serous ovarian carcinoma. Cancer, 2009, 115, 3897-3908.	4.1	29
269	SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters. International Journal of Cancer, 2020, 146, 1553-1567.	5.1	29
270	Targeting progesterone signaling prevents metastatic ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 31993-32004.	7.1	29

#	Article	IF	Citations
271	In Vitro Assay of Endotoxin by the Inhibition of Macrophage Migration. Journal of Bacteriology, 1967, 93, 15-20.	2.2	29
272	HETEROGENEITY OF THE CELLULAR IMMUNE RESPONSE. Journal of Experimental Medicine, 1971, 133, 187-201.	8.5	28
273	Homologous and heterologous desensitization of proto-oncogene cfos expression in murine peritoneal macrophages. Journal of Cellular Physiology, 1987, 131, 36-42.	4.1	28
274	Heterogeneity of antigen expression in benign and malignant breast and ovarian epithelial cells. International Journal of Cancer, 1989, 43, 55-60.	5.1	28
275	CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer. Gynecologic Oncology, 1990, 36, 161-165.	1.4	28
276	The tumor suppressor geneARHI(DIRAS3)inhibits ovarian cancer cell migration through multiple mechanisms. Cell Adhesion and Migration, 2013, 7, 232-236.	2.7	28
277	CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis. PLoS ONE, 2015, 10, e0131833.	2.5	28
278	Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare. Transactions of the American Clinical and Climatological Association, 2004, 115, 233-47; discussion 247-8.	0.5	28
279	Ploidy analysis of epithelial ovarian cancers using image cytometry. Gynecologic Oncology, 1992, 44, 61-65.	1.4	27
280	The biology of ovarian cancer. Current Opinion in Oncology, 1993, 5, 900-908.	2.4	27
281	Long-Term Follow-up of the Stockholm Screening Study on Ovarian Cancer. Gynecologic Oncology, 2000, 79, 466-470.	1.4	27
282	In vivoÂmodeling of metastatic human high-grade serous ovarian cancer in mice. PLoS Genetics, 2020, 16, e1008808.	3.5	27
283	The early competence genes JE and KC are differentially regulated in murine peritoneal macrophages in response to lipopolysaccharide. Biochemical and Biophysical Research Communications, 1987, 149, 969-974.	2.1	26
284	High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. Cancer Chemotherapy and Pharmacology, 1989, 23, 377-383.	2.3	26
285	Heterogeneity of antigen expression in advanced epithelial ovarian cancer. American Journal of Obstetrics and Gynecology, 1990, 162, 883-888.	1.3	26
286	Clinical application of oxaliplatin in epithelial ovarian cancer. International Journal of Gynecological Cancer, 2006, 16, 1717-1732.	2.5	26
287	Anti-HER2 Antibody Trastuzumab Inhibits CDK2-Mediated NPAT and Histone H4 Expression via PI3K Pathway. Cell Cycle, 2006, 5, 1654-1661.	2.6	26
288	Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. Journal of Hematology and Oncology, 2010, 3, 9.	17.0	26

#	Article	IF	Citations
289	The Role of p27 Kip1 in Dasatinib-Enhanced Paclitaxel Cytotoxicity in Human Ovarian Cancer Cells. Journal of the National Cancer Institute, 2011, 103, 1403-1422.	6.3	26
290	The role of vascular endothelial growth factor, interleukin 8, and insulinlike growth factor in sustaining autophagic DIRAS3â€induced dormant ovarian cancer xenografts. Cancer, 2019, 125, 1267-1280.	4.1	26
291	Directed evolution of cyclic peptides for inhibition of autophagy. Chemical Science, 2021, 12, 3526-3543.	7.4	26
292	The Role of Tumor Markers in Gynecologic Oncology. Obstetrical and Gynecological Survey, 1990, 45, 570-577.	0.4	25
293	Expression of cell regulatory proteins in ovarian borderline tumors. , 1996, 77, 2092-2098.		25
294	Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplantation, 2004, 33, 1219-1224.	2.4	24
295	Eradication of Microscopic Lymph Node Metastases After Injection of Living BeG Adiacent to the Primary Tumor. Journal of the National Cancer Institute, 1975, 55, 1345-1352.	6.3	23
296	A Comparison of Immunohistochemistry, Two-Color Immunofluorescence, and Flow Cytometry with Cell Sorting for the Detection of Micrometastatic Breast Cancer in the Bone Marrow. Stem Cells and Development, 1996, 5, 57-62.	1.0	23
297	Is OVX1 a Suitable Marker for Endometrial Cancer?. Gynecologic Oncology, 1997, 65, 291-296.	1.4	23
298	Specific Keynote: Molecular Therapeutics in Ovarian Cancer. Gynecologic Oncology, 2003, 88, S88-S92.	1.4	23
299	Targeting Aurora kinases in ovarian cancer. Expert Opinion on Therapeutic Targets, 2006, 10, 77-85.	3.4	23
300	ARHI (DIRAS3), an imprinted tumour suppressor gene, binds to importins and blocks nuclear import of cargo proteins. Bioscience Reports, 2010, 30, 159-168.	2.4	23
301	Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. Frontiers in Oncology, 2013, 3, 58.	2.8	23
302	Loss of PFKFB4 induces cell death in mitotically arrested ovarian cancer cells. Oncotarget, 2017, 8, 17960-17980.	1.8	23
303	Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer. International Journal of Cancer, 1991, 49, 704-710.	5.1	22
304	Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass. International Journal of Cancer, 2000, 89, 519-523.	5.1	22
305	Epac1 knockdown inhibits the proliferation of ovarian cancer cells by inactivating AKT/Cyclin D1/CDK4 pathway in vitro and in vivo. Medical Oncology, 2016, 33, 73.	2.5	22
306	In Vivo Optical Detection and Spectral Triangulation of Carbon Nanotubes. ACS Applied Materials & Interfaces, 2017, 9, 41680-41690.	8.0	22

#	Article	IF	Citations
307	Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer. Cancers, 2019, 11, 596.	3.7	22
308	6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers. Clinical Cancer Research, 2019, 25, 5702-5716.	7.0	22
309	Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. , 1999, 82, 525-531.		21
310	Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. Gynecologic Oncology, 2008, 108, 652-657.	1.4	21
311	Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. Cell Cycle, 2010, 9, 140-146.	2.6	21
312	Human epididymis protein 4 antigenâ€autoantibody complexes complement cancer antigen 125 for detecting earlyâ€stage ovarian cancer. Cancer, 2020, 126, 725-736.	4.1	21
313	INDUCTION OF TUMOR IMMUNITY BY INTRATUMORAL CHEMOTHERAPY. Annals of the New York Academy of Sciences, 1976, 276, 565-572.	3.8	20
314	A study of the NB/70K and CA 125 monoclonal antibody radioimmunoassays for measuring serum antigen levels in ovarian cancer patients. American Journal of Obstetrics and Gynecology, 1985, 152, 911-913.	1.3	20
315	Elimination of clonogenic breast cancer cells from human bone marrow. A comparison of immunotoxin treatment with chemoimmunoseparation using 4-hydroperoxycyclophosphamide, monoclonal antibodies, and magnetic microspheres. Cancer, 1991, 68, 1272-1278.	4.1	20
316	Oncogenes in Ovarian Cancer. Hematology/Oncology Clinics of North America, 1992, 6, 813-827.	2.2	20
317	Molecular approaches to prevention and detection of epithelial ovarian cancer. Journal of Cellular Biochemistry, 1995, 59, 219-222.	2.6	20
318	Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. , 1999, 86, 1251-1257.		20
319	Heregulin-induced apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 2002, 7, 483-491.	4.9	20
320	A Bayesian Approach to Doseâ€"Response Assessment and Synergy and Its Application to In Vitro Doseâ€"Response Studies. Biometrics, 2010, 66, 1275-1283.	1.4	20
321	Conquering Cancer in Our Lifetime: New Diagnostic and Therapeutic Trends. Clinical Chemistry, 2013, 59, 1-3.	3.2	20
322	Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models. BMC Cancer, 2016, 16, 824.	2.6	20
323	Amino Acid Deprivation-Induced Autophagy Requires Upregulation of DIRAS3 through Reduction of E2F1 and E2F4 Transcriptional Repression. Cancers, 2019, 11, 603.	3.7	20
324	Circulating Cancer Biomarkers. Cancers, 2021, 13, 802.	3.7	20

#	Article	IF	Citations
325	DIRAS3: An Imprinted Tumor Suppressor Gene that Regulates RAS and PI3K-driven Cancer Growth, Motility, Autophagy, and Tumor Dormancy. Molecular Cancer Therapeutics, 2022, 21, 25-37.	4.1	20
326	Carcinoma of the Pancreas. Annals of Surgery, 1985, 202, 440-445.	4.2	19
327	High-Dose Topotecan, Melphalan, and Cyclophosphamide (TMC) with Stem Cell Support: A New Regimen for the Treatment of Advanced Ovarian Cancer. Gynecologic Oncology, 2001, 82, 420-426.	1.4	19
328	Caspase-3 Substrates for Noninvasive Pharmacodynamic Imaging of Apoptosis by PET/CT. Bioconjugate Chemistry, 2018, 29, 3180-3195.	3.6	19
329	Analysis of RAS protein interactions in living cells reveals a mechanism for pan-RAS depletion by membrane-targeted RAS binders. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12121-12130.	7.1	19
330	Comparison of a rabbit heteroantiserum and a murine monoclonal antibody raised against a human epithelial ovarian carcinoma cell line. American Journal of Obstetrics and Gynecology, 1983, 146, 607-612.	1.3	18
331	Gynecologic tumor markers. Journal of Surgical Oncology, 1990, 6, 305-313.	1.4	18
332	Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. Cancer, 1995, 76, 1615-1620.	4.1	18
333	Transfection of Human Ovarian Cancer Cells with the HER-2/neuReceptor Tyrosine Kinase Induces a Selective Increase in PTP-H1, PTP-1B, and PTP-Î± Expression. Gynecologic Oncology, 1996, 61, 233-240.	1.4	18
334	Physiologic and Pathologic Drug Resistance in Ovarian Carcinoma: A Hypothesis Based on a Clonal Progression Model. Acta OncolÃ³gica, 1998, 37, 629-640.	1.8	18
335	Project Zero Delay: A Process for Accelerating the Activation of Cancer Clinical Trials. Journal of Clinical Oncology, 2009, 27, 4433-4440.	1.6	18
336	Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women. Cancers, 2020, 12, 1931.	3.7	18
337	A combination of two immunotoxins exerts synergistic cytotoxic activity against human breast-cancer cell lines. International Journal of Cancer, 1992, 51, 772-779.	5.1	17
338	Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer. Cancer Prevention Research, 2019, 12, 391-400.	1.5	17
339	SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers. Journal of Clinical Investigation, 2022, 132, .	8.2	17
340	Determination of Proliferation Index in Advanced Ovarian Cancer Using Quantitative Image Analysis. American Journal of Clinical Pathology, 1993, 99, 736-740.	0.7	16
341	OVX1 Radioimmunoassay Results Are Dependent on the Method of Sample Collection and Storage. Clinical Chemistry, 1999, 45, 692-694.	3.2	16
342	In vitro model of normal, immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer. Gynecologic Oncology, 2005, 98, 182-192.	1.4	16

#	Article	IF	Citations
343	DIRAS3-Derived Peptide Inhibits Autophagy in Ovarian Cancer Cells by Binding to Beclin1. Cancers, 2019, 11, 557.	3.7	16
344	Potentially inappropriate medications defined by STOPP criteria in older patients with breast and colorectal cancer. Journal of Geriatric Oncology, 2019, 10, 705-708.	1.0	16
345	Next steps in the early detection of ovarian cancer. Communications Medicine, 2021, 1, .	4.2	16
346	Monocyte chemotaxis mediated by formyl-methionyl-leucyl-phenylalanine conjugated with monoclonal antibodies against human ovarian carcinoma. International Journal of Immunopharmacology, 1983, 5, 307-314.	1.1	15
347	Antigenic heterogeneity in human ovarian cancer. Gynecologic Oncology, 1990, 38, 12-16.	1.4	15
348	The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-a chain immunotoxin. International Journal of Cancer, 1994, 59, 242-247.	5.1	15
349	Use of Rasâ€Transformed Human Ovarian Surface Epithelial Cells as a Model for Studying Ovarian Cancer. Methods in Enzymology, 2006, 407, 660-676.	1.0	15
350	A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancer. Cancer Chemotherapy and Pharmacology, 2011, 68, 1033-1044.	2.3	15
351	A MYC-Driven Plasma Polyamine Signature for Early Detection of Ovarian Cancer. Cancers, 2021, 13, 913.	3.7	15
352	Immunohistochemical expression of TAG-72 in normal and malignant endometrium: Correlation of antigen expression with estrogen receptor and progesterone receptor levels. American Journal of Obstetrics and Gynecology, 1989, 161, 1258-1263.	1.3	14
353	Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen.. Journal of Clinical Oncology, 1992, 10, 1057-1065.	1.6	14
354	Ovarian cancer identified through screening with serum markers but not by pelvic imaging. International Journal of Gynecological Cancer, 1999, 9, 497-501.	2.5	14
355	Reproducibility of SELDI Spectra across Time and Laboratories. Cancer Informatics, 2011, 10, CIN.S6438.	1.9	14
356	The origin of ovarian cancer. BJOG: an International Journal of Obstetrics and Gynaecology, 2012, 119, 134-136.	2.3	14
357	NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms. Oncotarget, 2016, 7, 3018-3032.	1.8	14
358	Transfection of Ovarian Cancer Cells with Tumor Necrosis Factor-Î± (TNF-Î±) Antisense mRNA Abolishes the Proliferative Response to Interleukin-1 (IL-1) but Not TNF-Î±. Gynecologic Oncology, 1994, 53, 59-63.	1.4	13
359	Imprinted tumor suppressor gene ARHI induces apoptosis correlated with changes in DNA methylation in pancreatic cancer cells. Molecular Medicine Reports, 2010, 3, 581-7.	2.4	13
360	Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. Cancer Biology and Therapy, 2012, 13, 1034-1041.	3.4	13

#	Article	IF	Citations
361	How will we recruit, train, and retain physicians and scientists to conduct translational cancer research?. Cancer, 2015, 121, 806-816.	4.1	13
362	A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-Î². Investigational New Drugs, 2018, 36, 1103-1109.	2.6	13
363	Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action.. Journal of Clinical Investigation, 1993, 92, 2440-2447.	8.2	13
364	Nature of the immunogen in crystalline serum albumins. Immunochemistry, 1970, 7, 119-123.	1.2	12
365	Brief Communication: Presence of A-Type and Absence of C-Type Virus Particles in a Chemically Induced Guinea Pig Hepatoma. Journal of the National Cancer Institute, 1974, 53, 591-593.	6.3	12
366	Translational researchÂâ€“ traffic on the bridge. Biomedicine and Pharmacotherapy, 2001, 55, 565-571.	5.6	12
367	Simultaneous Measurement of 92 Serum Protein Biomarkers for the Development of a Multiprotein Classifier for Ovarian Cancer Detection. Cancer Prevention Research, 2019, 12, 171-184.	1.5	12
368	Immunochemical characterization and radioimmunometric petection of molecules shed by human ovarian cancer. International Journal of Cancer, 1987, 40, 592-597.	5.1	11
369	Molecular approaches to management of epithelial ovarian cancer. International Journal of Gynecological Cancer, 2000, 10, 2-7.	2.5	11
370	A new standard combination for recurrent ovarian cancer?. Nature Reviews Clinical Oncology, 2010, 7, 559-560.	27.6	11
371	SIK2 promotes ovarian cancer cell motility and metastasis by phosphorylating MYLK. Molecular Oncology, 2022, 16, 2558-2574.	4.6	11
372	OVX1 as a marker for early stage endometrial carcinoma. Cancer, 1994, 73, 1855-1858.	4.1	10
373	Preoperative evaluation of macrophage colony-stimulating factor levels in patients with endometrial cancer. American Journal of Obstetrics and Gynecology, 1996, 174, 1316-1319.	1.3	10
374	Specific Keynote: Chemoprevention of Ovarian Cancer: The Journey Begins. Gynecologic Oncology, 2003, 88, S59-S66.	1.4	10
375	Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition. Cancer, 2020, 126, 3579-3592.	4.1	10
376	A Novel Salt Inducible Kinase 2 Inhibitor, ARN-3261, Sensitizes Ovarian Cancer Cell Lines and Xenografts to Carboplatin. Cancers, 2021, 13, 446.	3.7	10
377	Antigenic heterogeneity among burkitt's lymphoma cells surviving treatment with monoclonal antibody and complement. Leukemia Research, 1986, 10, 35-42.	0.8	9
378	Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer. Cancer, 1992, 70, 2137-2142.	4.1	9

#	Article	IF	Citations
379	High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Bone Marrow Transplantation, 2000, 25, 1137-1140.	2.4	9
380	Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer. Oncogene, 2000, 19, 6277-6285.	5.9	9
381	Proteome Profiling Uncovers an Autoimmune Response Signature That Reflects Ovarian Cancer Pathogenesis. Cancers, 2020, 12, 485.	3.7	9
382	Communication skills training in oncology. Cancer, 1999, 86, 887-897.	4.1	9
383	Destruction of Syngeneic Tumors by Tuberculin-Stimulated Peritoneal Exudate Cells From Guinea Pigs Immunized to Mycobacterium bovis (Strain BCG). Journal of the National Cancer Institute, 1974, 53, 541-546.	6.3	8
384	Specificity of Heteroantisera Developed Against Purified Populations of Intact Murine Ovarian Carcinoma Cells23. Journal of the National Cancer Institute, 1980, 64, 365-372.	6.3	8
385	The Use of Tumor Markers in the Management of Patients with Gynecologic Carcinomas. Clinical Obstetrics and Gynecology, 1992, 35, 45-54.	1.1	8
386	The effect of interferon gamma on epidermal growth factor receptor expression in normal and malignant ovarian epithelial cells. American Journal of Obstetrics and Gynecology, 1992, 167, 1877-1882.	1.3	8
387	Combination of 4-HPR and oral contraceptive in monkey model of chemoprevention of ovarian cancer. Frontiers in Bioscience - Landmark, 2007, 12, 2260.	3.0	8
388	Local Antitumor Activity of a Primary and an Anamnestic Response to a Syngeneic Guinea Pig Hepatoma. Journal of the National Cancer Institute, 1975, 55, 989-994.	6.3	7
389	Progress in Radioimmunotherapy. New England Journal of Medicine, 1993, 329, 1266-1268.	27.0	7
390	Phase Iâ€“II Vinorelbine (NavelbineÂ®) by Continuous Infusion in Patients with Metastatic Breast Cancer: Cumulative Toxicities Limit Dose Escalation. Cancer Investigation, 2001, 19, 459-466.	1.3	7
391	Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening. American Journal of Obstetrics and Gynecology, 2014, 210, 257.e1-257.e6.	1.3	7
392	Clinical Applications of Monoclonal Antibodies in Acute Leukemia. Annals of the New York Academy of Sciences, 1984, 428, 308-317.	3.8	6
393	4-HPR modulates gene expression in ovarian cells. International Journal of Cancer, 2006, 119, 1005-1013.	5.1	6
394	Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer, 1995, 76, 2092-2096.	4.1	6
395	Radioiodinated Antibody Targeting of the HER-2/neu Oncoprotein. Nuclear Medicine and Biology, 1997, 24, 451-459.	0.6	6
396	Brief Communication: Intracolonlc Injection of BeG in the Rhesus Monkey. Journal of the National Cancer Institute, 1974, 53, 1423-1426.	6.3	5

#	Article	IF	Citations
397	Suppression of Diacylglycerol Levels by Antibodies Reactive with the c-erbB-2 (HER-2/neu) Gene Product p185c-erbB-2in Breast and Ovarian Cancer Cell Lines. Gynecologic Oncology, 1998, 70, 49-55.	1.4	5
398	Biomarkers for ovarian cancer: New technologies and targets to address persistently unmet needs. Cancer Biomarkers, 2011, 8, 161-166.	1.7	5
399	Nuclear HKIIâ€“P-p53 (Ser15) Interaction is a Prognostic Biomarker for Chemoresponsiveness and Glycolytic Regulation in Epithelial Ovarian Cancer. Cancers, 2021, 13, 3399.	3.7	5
400	Monitoring Epithelial Ovarian Cancer. Laboratory Medicine, 1985, 16, 315-318.	1.2	4
401	Detection of a novel marker in the bronchial secretions of patients with non-small cell lung cancer using the 4B5 monoclonal antibody. Cancer, 1992, 69, 2894-2904.	4.1	4
402	Current Challenges and Future Directions in the Management of Ovarian Cancer: Proceedings of the First Global Workshop on Ovarian Cancer. Clinical Ovarian Cancer & Other Gynecologic Malignancies, 2010, 3, 81-97.	0.2	4
403	The National Cancer Institute Early Detection Research Network: Two Decades of Progress. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2396-2400.	2.5	4
404	Recent advances in the immunodiagnosis of epithelial ovarian carcinoma. Cancer Treatment and Research, 1985, , 23-35.	0.5	4
405	The Immunobiology of Ovarian Carcinoma. Cancer Treatment and Research, 1983, , 187-226.	0.5	4
406	Abstract 1864: Feasibility of magnetic relaxometry for early ovarian cancer detection: preliminary evaluation of sensitivity and specificity in cell culture and in mice. Cancer Research, 2017, 77, 1864-1864.	0.9	4
407	Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors. Tumor Biology, 2021, 43, 355-365.	1.8	4
408	Development of a Multiprotein Classifier for the Detection of Early Stage Ovarian Cancer. Cancers, 2022, 14, 3077.	3.7	4
409	The half-life of aryl hydrocarbon (benzo(a)pyrene) hydroxylase in human blood monocytes. Chemico-Biological Interactions, 1976, 14, 379-382.	4.0	3
410	Biology and therapy with biologic agents in gynecologic cancer. Current Opinion in Oncology, 1992, 4, 946-954.	2.4	3
411	Screening for ovarian cancer. Multiple markers may outperform CA 125 alone.. BMJ: British Medical Journal, 1993, 306, 1684-1685.	2.3	3
412	Elevated serum levels of macrophage colony-stimulating factor and OVX1, 11 months prior to the diagnosis of stage IC ovarian cancer. International Journal of Gynecological Cancer, 1996, 6, 156-158.	2.5	3
413	Conclusions and recommendations from the Helene Harris Memorial Trust SixthBiennial International Forum on Ovarian Cancer, May 10-14, 1997, LosAngeles, California, USA. International Journal of Gynecological Cancer, 1997, 7, 416-424.	2.5	3
414	Alterations in Oncogenes, Tumor Suppressor Genes, and Growth Factors Associated with Epithelial Ovarian Cancers. , 2001, 39, 37-48.		3

#	Article	IF	Citations
415	Biomarkers and clinical trial design. Gynecologic Oncology, 2006, 103, 3-5.	1.4	3
416	Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor initiating cells. JCI Insight, 2021, 6, .	5.0	3
417	Tumor Suppressor Genes. Cancer Treatment and Research, 2009, 149, 109-129.	0.5	3
418	Abstract 2838: TP53 autoantibody can detect CA125 screen negative ovarian cancer cases and can be elevated prior to CA125 in preclinical ovarian cancer. Cancer Research, 2015, 75, 2838-2838.	0.9	3
419	Directed Evolution of PD-L1-Targeted Affibodies by mRNA Display. ACS Chemical Biology, 2022, 17, 1543-1555.	3.4	3
420	New approach to serotherapy of human ovarian carcinoma. Gynecologic Oncology, 1980, 10, 370.	1.4	2
421	Reply to Davies et al. American Journal of Obstetrics and Gynecology, 1985, 151, 420.	1.3	2
422	CA 125 levels in patients with ovarian carcinoma undergoing autologous bone marrow transplantation. American Journal of Obstetrics and Gynecology, 1989, 160, 354-355.	1.3	2
423	Reactivity of Polyclonal and Two Monoclonal Antibodies with Cell Subsets Isolated from Cystic Fluids of Ovarian Serous Neoplasms. Tumori, 1990, 76, 505-510.	1.1	2
424	Ha-ras polymorphisms in epithelial ovarian cancer. Gynecologic Oncology, 1992, 45, 299-302.	1.4	2
425	Sensitive and specific detection of the 4B5 antigen in bronchial lavage specimens from patients with primary bronchogenic carcinoma. Cancer, 1992, 70, 1115-1123.	4.1	2
426	General Keynote: Molecular Therapeutics and Pharmocogenomics. Gynecologic Oncology, 2003, 88, S84-S87.	1.4	2
427	Molecular Pathogenesis of Ovarian Cancer. , 2015, , 531-548.e2.		2
428	Abstract 2051: DNA (cytosine-5-)-methyltransferases 3A (DNMT3A) is a direct target of miR-194 in breast cancer. Cancer Research, 2010, 70, 2051-2051.	0.9	2
429	Abstract LB-296: Discovery of ARN-3261 as a potent, selective, orally available SIK2 inhibitor for treating ovarian, endometrial, primary peritoneal, fallopian tube, and triple negative breast cancers. Cancer Research, 2017, 77, LB-296-LB-296.	0.9	2
430	Elevation of CA-125 prior to recurrence of ovarian cancer. Gynecologic Oncology, 1985, 20, 263-264.	1.4	1
431	Molecular Pathogenesis of Epithelial Ovarian Cancer. , 2008, , 441-454.		1
432	Reply to Comment on â€œOsteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancerâ€•Cancers 2019, 11, 596: Markers for Early Detection of Ovarian Cancer. Cancers, 2019, 11, 1386.	3.7	1

#	Article	IF	Citations
433	Abstract 83: Structural and biochemical properties of DIRAS3 N-terminal extension that permit its function as a tumor suppressor of oncogenic K-RAS. , 2021, , .		1
434	Abstract 1999: DIRAS3 induces autophagy and enhances sensitivity to anti-autophagic therapy in KRAS-driven pancreatic and ovarian carcinomas. , 2021, , .		1
435	Abstract 324: SIK2 inhibitors regulate DNA repair pathway and sensitize ovarian cancer to PARP1 inhibitors. , 2018, , .		1
436	Abstract A43: DIRAS1 and DIRAS2 are tumor suppressor candidates that inhibit cell growth, motility, and proliferation while regulating autophagy in ovarian cancer.. , 2016, , .		1
437	Validation of a multi-marker panel for early detection of ovarian cancer.. Journal of Clinical Oncology, 2016, 34, 5570-5570.	1.6	1
438	Detection and measurement of HER2+ breast cancer cells using tumor-targeted iron oxide nanoparticles and magnetic relaxometry.. Journal of Clinical Oncology, 2018, 36, e13019-e13019.	1.6	1
439	Abstract 4540: Follicle-stimulating hormone (FSH) enhances the proliferation of epithelial ovarian cancer cells by activating transient receptor potential channel C3 (TRPC3). , 2011, , .		1
440	Abstract 749: Highly potent and orally available SIK2 inhibitors block growth of human ovarian cancer cells in culture and xenografts. , 2014, , .		1
441	Abstract 4987: IL8, VEGF and IGF-1 rescue ovarian cancer cells undergoing ARHI-mediated- autophagic cell death. , 2015, , .		1
442	Abstract 3032: A novel compound ARN-3236 inhibits SIK2 and sensitizes ovarian cancer to paclitaxel. Cancer Research, 2016, 76, 3032-3032.	0.9	1
443	Abstract LB-176: HE4 antigen-autoantibody complexes complement CA125 for detecting early stage ovarian cancer and can be elevated with CA125 in preclinical ovarian cancer. , 2018, , .		1
444	Molecular targets for epithelial ovarian cancer. , 0, , 606-618.		0
445	801 ABSENCE OF COMMON ALL ANTIGEN ON NORMAL PLURIPOTENTIAL MYELOID, ERYTHROID AND GRANULOCYTE PROGENITORS. Pediatric Research, 1981, 15, 576-576.	2.3	0
446	Monocyte chemotaxis mediated by f-MET-LEU-PHE (fMLP) conjugated with monoclonal anti-bodies against human ovarian carcinoma. International Journal of Immunopharmacology, 1982, 4, 285.	1.1	0
447	Monitoring growth of human ovarian carcinoma with a radioimmunoassay for antigen(s) defined by a murine monoclonal antibody (0C125). Gynecologic Oncology, 1983, 15, 135.	1.4	0
448	Clinical and Laboratory Directions for Ovarian Cancer Research. Gynecologic Oncology, 1994, 55, S164-S167.	1.4	0
449	Characterization of the ARHI Tumor-Suppressor as a Target for Gene Therapy in Ovarian Cancer*. Geburtshilfe Und Frauenheilkunde, 2002, 62, 870-876.	1.8	0
450	Molecular Mechanisms of Pathogenesis and Progression of Epithelial Ovarian Cancer. , 2004, , 625-645.		0

#	Article	IF	Citations
451	ARHI (DIRAS 3), an Imprinted Tumor Suppressor Gene, Binds to Importins, and Blocks Nuclear Translocation of Stat3. Nature Precedings, 2008, , .	0.1	0
452	p27Kip1 as a Biomarker and Target for Treatment of Cancer. , 2010, , 215-233.		0
453	Targeting therapies in cancer: opportunities in ovarian cancer. , 0, , 167-182.		0
454	Perception of risk, cancer worry, anxiety, and acceptability of screening among low-risk women undergoing ovarian cancer screening with the risk of ovarian cancer algorithm. Gynecologic Oncology, 2012, 125, S116-S117.	1.4	0
455	A 2-Stage Ovarian Cancer Screening Strategy Using the Risk of Ovarian Cancer Algorithm (ROCA) Identifies Early-Stage Incident Cancers and Demonstrates High Positive Predictive Value. Obstetrical and Gynecological Survey, 2014, 69, 26-27.	0.4	0
456	Recurrent Ovarian Cancer: When to Treat and How to Assess. , 2014, , 17-27.		0
457	If looks could kill: morphologic subtypes of high-grade serous ovarian cancer. Gynecologic Oncology, 2021, 162, S20-S21.	1.4	0
458	Ovarian Cancer Screening. , 2010, , 87-107.		0
459	Abstract 4288: Targeted therapy against aldehyde dehydrogenase in ovarian cancer. , 2010, , .		0
460	Abstract 4993: ARHI is required for induction of beclin-1/PI(3)K class III-mediated autophagy. , 2010, , .		0
461	Abstract 4567: Urine biomarkers outperform serum biomarkers in the diagnosis of various human cancers. , 2010, , .		0
462	Abstract 4679: Integrin and FAK signaling regulate ARHI-induced autophagy. , 2010, , .		0
463	Abstract 2097: ARHI (DiRAS3): A novel component in the formation of the autophagy initiation complex. , 2011, , .		0
464	Abstract 3779: ARHI-induced autophagy is mediated through activation of FoxO3a and induction of its target genes to promote the formation of autophagic complexes. , 2011, , .		0
465	Abstract 4822: Nonsense mediated decay defines deleterious TP53 mutations and tumor aggressiveness in ovarian cancer. , 2011, , .		0
466	Abstract 4000: Trastuzumab targeting of HER2 upregulates miRNA-194 and downregulates profilin 2 and DNMT3A in HER2 positive breast cancer. , 2011, , .		0
467	Abstract 1247: ARHI downregulates PI3K and Ras-MAP signaling and induces autophagy by promoting integrin and EGFR membrane protein degradation. , 2012, , .		0
468	Abstract 3057: CDK5 modulates the cell cycle, apoptosis and paclitaxel sensitivity in human ovarian cancer cells with wild-type p53 function. , 2012, , .		0

#	Article	IF	Citations
469	Abstract 3573: Urine and serum biomarkers as early detection tools for ovarian cancer. , 2012, , .		0
470	Abstract 2182: Epigenetic regulation and growth suppression by NDN, an imprinted tumor suppressor gene whose expression is decreased in epithelial ovarian cancers. , 2012, , .		0
471	Abstract 3495: Multiplexed detection of early-stage ovarian cancer biomarkers using a microfluidic bead-based immunosensor.. , 2013, , .		0
472	Abstract 4766: Follicle stimulating hormone (FSH) inhibits apoptosis in ovarian cancer cell through regulating OCT4 stem cell signal pathway.. , 2013, , .		0
473	Abstract 3473: Intra-person and inter-person biomarker variation for modeling longitudinal values of ovarian cancer early detection biomarkers.. , 2013, , .		0
474	The Role of Angiogenesis, Growth Arrest and Autophagy in Human Ovarian Cancer Xenograft Models for Tumor Dormancy. , 2014, , 99-109.		0
475	Abstract 3762: Downregulation of TRPC3 enhances sensitivity to cisplatin and inhibits motility in epithelial ovarian cancer. , 2014, , .		0
476	Abstract 2311: NDN, an imprinted tumor suppressor gene inhibits ovarian cancer cell growth and motility and is downregulated by genetic and epigenetic mechanisms. , 2014, , .		0
477	Abstract 5105: The imprinted tumor suppressor gene NDN inhibits cell motility in ovarian cancer by reactivating FAK and RhoA. , 2015, , .		0
478	Abstract 3456: MUC16/CA125, TNFÎ± and IFNÎ³ are co-expressed in malignant gynecologic neoplasms. , 2015, , .		0
479	Abstract 3827: Histone methytransferase SMYD3 promotes invasion in ovarian carcinoma spheroids. , 2015, , .		0
480	Abstract 4028: ARHI plays a critical role in ovarian cancer tumor dormancy by inhibition of angiogenesis switch. , 2015, , .		0
481	Abstract AS12: Integrating genomics, transcriptomics, and proteomics for the discovery of novel biomarkers to complement CA125 in ovarian cancer early detection. , 2015, , .		0
482	Abstract PR18: Survival of ARHI-induced dormant autophagic cell death in vivo requires permissive levels of VEGF, IL-8, and IGF-1 in the tumor microenvironment.. , 2016, , .		0
483	Abstract LB-119: Single-cell live imaging of paclitaxel-resistant cancer cell generation. , 2016, , .		0
484	Abstract 1151: IL-8, VEGF and IGF-1 play the important role in ARHI mediated-tumor dormancy in ovarian cancer. , 2016, , .		0
485	Abstract 3659: DIRAS1 and DIRAS2 are novel ovarian cancer tumor suppressors that regulate cell growth, motility and autophagy. , 2016, , .		0
486	Abstract 438: Development of an autoantibody panel that reflects disease pathogenesis in ovarian cancer. , 2016, , .		0

#	Article	IF	Citations
487	Abstract 4670: Combinations of kinase siRNAs potentiates paclitaxel sensitivity in ovarian cancer. , 2016, , .		0
488	Abstract 3564: Silencing pfkfb2 enhances paclitaxel sensitivity by modulating metabolism of p53 wt ovarian and breast cancer cells and xenografts. , 2017, , .		0
489	Abstract 887: Magnetic relaxometry detection of stealth, antibody-targeted micellar iron oxide nanoparticles in-vivo. , 2017, , .		0
490	Abstract 3313: Autophagic ovarian cancer cells exhibit substantially enhanced sensitivity to Crizotinib. , 2017, , .		0
491	Abstract 888: Volumetric reconstruction of targeted nanoparticles for superparamagnetic relaxometry. , 2017, , .		0
492	Abstract 3317: Autophagy protects ovarian cancer cells from olaparib-induced toxicity. , 2017, , .		0
493	Abstract 1325: DIRAS3 (ARHI) is required for amino acid-mediated autophagy and nutrient deprivation in dormant ovarian cancers. , 2018, , .		0
494	Abstract 912: Macrophage inhibitory factor (MIF), osteopontin (OPN) and anti-interleukin-8 (IL-8) autoantibodies (AAb) complement CA125 for detection of early-stage ovarian cancer. , 2019, , .		0
495	Abstract 4263: Autophagic ovarian cancer cells exhibit substantially enhanced sensitivity to ALK inhibition. , 2019, , .		0
496	Abstract 4083: Crizotinib improves the therapeutic efficacy of olaparib in ovarian cancer. , 2020, , .		0
497	Abstract 5210: Novel SIK2 inhibitors sensitize ovarian and breast cancer to PARP inhibitors. , 2020, , .		0
498	Abstract 3816: Corilagin could help to overcome PARP inhibitor resistance by inhibiting ERK signaling pathways. , 2019, , .		0
499	Abstract 4768: PARP inhibitor-induced autophagy provides an adaptive mechanism of drug resistance in preclinical models of ovarian cancer. , 2019, , .		0
500	Absence of common ALL antigen on normal bipotent myeloid, erythroid, and granulocyte progenitors. Blood, 1981, 58, 333-336.	1.4	0